HKEX Stock Code: 01093English|繁體|简体

Results for the first quarter of 2026

  • Revenue RMB6,465M, -7.8%
  • Reported profit attributable to shareholders of the Company RMB860M, -41.8%
  • Underlying profit attributable to shareholders of the Company RMB842M, -40.3%
  • Basic earnings per share (based on reported profit) RMB7.54 cents, -41.6%

Financial Reports

2025 Annual Report

Highlight - Results for the first quarter of 2026

Revenue
RMB6,465M, -7.8%
Reported profit attributable to shareholders of the Company
RMB860M, -41.8%
Underlying profit attributable to shareholders of the Company
RMB842M, -40.3%
Basic earnings per share (based on reported profit)
RMB7.54 cents, -41.6%

Corporate Governance

Corporate Governance

Latest News

Jun
23
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
22
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
22
FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION

Financial Calendar

May
28
Shareholders Meeting
May
27
Board Meeting
May
27
2026Q1 Results Announcement
Mar
25
2025 Annual Results Announcement
Mar
25
Board Meeting
* Subject to change.
>> more

Financial Reports

Financial Reports

Financial Summary

Financial Summary

IR Contacts

Address : Suite 3206, 32/F, Central Plaza,
18 Harbour Road, Wanchai, Hong Kong
Tel : (852) 2500 3144
Fax : (852) 2802 4552
E-mail : ir@cspc.hk
© Copyright 2026 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer